์ํ ๋ฐ์ฟ ์จ
**์ํ ๋ฐ์ฟ ์จ(Atovaquone)**์ ์ง์ฉ์ฑ์ด ๋์ ํฉ์ฑ ํ์ด๋๋ก์๋ํํ ํด๋ ผ๊ณ ํญ์์ถฉ์ ์ ๋๋ค. ์์ํ์์๋ ์น๋ฃ๊ฐ ๊น๋ค๋ก์ด ํน์ ์ง๋๊ธฐ ๋งค๊ฐ ์์ถฉ ๊ฐ์ผ ์น๋ฃ์ ํ์ ์ ์ธ ์ญํ ์ ํ๊ณ ์์ต๋๋ค. **์ฃผ์ ์์ ์ฉ๋:** * **๊ฐ์ ๋ฐ๋ฒ ์์ ๊น์๋(Babesia gibsoni) ๊ฐ์ผ:** ์์ง์ค๋ก๋ง์ด์ ๊ณผ ํจ๊ป ์๋์ง ํจ๊ณผ๋ฅผ ์ํด ์ฌ์ฉ๋ฉ๋๋ค. *B. gibsoni*๋ ์ด๋ฏธ๋์นด๋ธ์ ๊ฐ์ ์ ํต์ ์ธ ์น๋ฃ๋ฒ์ ๋ด์ฑ์ ๋ณด์ด๋ ๊ฒฝ์ฐ๊ฐ ๋ง์ ์ํ ํผ๋กํ๋ผ์ค๋ง์ ๋๋ค. ์ํ ๋ฐ์ฟ ์จ/์์ง์ค๋ก๋ง์ด์ ๋ณ์ฉ ์๋ฒ์ด ํ์ฌ ์ต์ฐ์ ์น๋ฃ๋ฒ์ ๋๋ค. * **๊ณ ์์ด์ ์ฌ์ดํ ์ค์ฆ(Cytauxzoon felis):** ์์ง์ค๋ก๋ง์ด์ ๊ณผ ๋ณ์ฉํ์ฌ ์ฌ์ฉํฉ๋๋ค. ์ฌ์ดํ ์ค์ฆ์ ๊ณ ์์ด์๊ฒ ๋งค์ฐ ์น๋ช ์ ์ธ ์ง๋๊ธฐ ๋งค๊ฐ ์งํ์ด๋ฉฐ, ์ด ์ฝ๋ฌผ ์กฐํฉ์ ์ ๊ทน์ ์ธ ๋ณด์กฐ ์๋ฒ(์์ก, ํคํ๋ฆฐ)๊ณผ ํจ๊ป ์์กด์จ์ ํฌ๊ฒ ํฅ์์์ผฐ์ต๋๋ค. * **๊ฐ์ ํํฌ์์ถฉ์ฆ(Pneumocystosis):** ๊ฐํ ์คํฐ์๋ง์ด๋๊ณ ์ฝ๋ฌผ์ ์ฌ์ฉํ ์ ์๊ฑฐ๋ ํจ๊ณผ๊ฐ ์์ ๋ ํํฌ์์ถฉ ํ๋ ด์ 2์ฐจ ์น๋ฃ์ ๋ก ์ฌ์ฉ๋ฉ๋๋ค. > **์์ ํ:** ์ํ ๋ฐ์ฟ ์จ์ ๋จ๋ ๋๋ ์์ง์ค๋ก๋ง์ด์ ๊ณผ ๋ณ์ฉ ์ ์ผ๋ฐ์ ์ผ๋ก ๋ด์ฝ์ฑ์ด ์ข์ง๋ง ๊ฐ๊ฒฉ์ด ๋งค์ฐ ๋น์๋๋ค. ์ธ์ฒด์ฉ ๋ณตํฉ์ ์ธ ๋ง๋ผ๋ก ยฎ(Malaroneยฎ, ์ํ ๋ฐ์ฟ ์จ/ํ๋ก๊ตฌ์๋)์ ํ๋ก๊ตฌ์๋ ์ฑ๋ถ์ด ์ฌ๊ฐํ ์์ฅ๊ด ๋ ์ฑ์ ์ ๋ฐํ๋ฏ๋ก ๊ฐ์๊ฒ **์ ๋ ๋์ฒดํ์ฌ ์ฌ์ฉํด์๋ ์ ๋ฉ๋๋ค**.
์์ฉ ๊ธฐ์ : Atovaquone acts as a selective and potent inhibitor of the protozoan mitochondrial electron transport chain. * It acts as a structural analogue of ubiquinone (Coenzyme Q). * It binds to the ubiquinol oxidation pocket of the **cytochrome bc1 complex** (Complex III) in the protozoan inner mitochondrial membrane. * This binding blocks electron transfer โ collapses the mitochondrial membrane potential โ halts the function of **dihydroorotate dehydrogenase**, an enzyme critically dependent on electron transport. * Inhibition of this enzyme prevents *de novo* pyrimidine synthesis. Because these specific protozoa lack the ability to salvage preformed pyrimidines from their host, they cannot synthesize DNA or RNA, leading to parasite death.
๋๋ฌผ ์ข ๋ณ ์ฉ๋
- Cytauxzoonosis (Cytauxzoon felis) ยท 15 mg/kg PO q8h ยท PO ยท q8h ยท Not specified ยท Give with azithromycin 10 mg/kg PO q24h. All cases were treated with IV fluids and most received heparin.
- Babesia gibsoni (Asian genotype) infections ยท 13.3 mg/kg PO q8h ยท PO ยท q8h ยท 10 days ยท Give with Azithromycin 10 mg/kg PO once daily. Reserve immunosuppressive therapy for cases that are not rapidly responding (3-5 days) to anti-protozoal therapy.
- Pneumocystosis ยท 15 mg/kg PO once daily ยท PO ยท q24h ยท 3 weeks ยท Considered second line therapy after potentiated sulfonamides.
์ฉ๋์ ๋ฉดํ ์์ ์ ๋ฌธ๊ฐ๋ฅผ ์ํ ์์ ์ฐธ๊ณ ์๋ฃ์ ๋๋ค. ํญ์ ์ต์ ๋ผ๋ฒจ๊ณผ ๊ฐ๋ณ ํ์์ ๋ํด ํ์ธํ์ญ์์ค.
ํฌ์ฌ ๊ฒฝ๋ก
๊ธ๊ธฐ
- Patients with a known hypersensitivity to atovaquone
- Patients with severe malabsorption syndromes
- Patients who cannot tolerate oral intake or cannot take the drug with a high-fat meal
์ด์๋ฐ์
- Gastrointestinal upset (nausea, vomiting, diarrhea)
- Rashes or hypersensitivity reactions
- Elevated liver enzymes
- CNS effects (headache, dizziness in humans)
- Fever
- Neutropenia and anemia (rare)
์ฝ๋ฌผ ์ํธ์์ฉ
- Metoclopramide ยท Can decrease atovaquone plasma concentrations
- Tetracycline ยท Can decrease atovaquone plasma concentrations
- Rifampin ยท Can decrease atovaquone plasma concentrations
๋ชจ๋ํฐ๋ง
- Clinical signs of efficacy (resolution of fever, lethargy, anemia)
- Serial CBCs to monitor anemia and platelet counts
- BUN, liver enzymes, and serum potassium (hypokalemia) in severe cases
- PCR testing at 60 days and 90 days post-therapy to confirm 'clearing' of B. gibsoni
๊ณผ์ฉ๋
Limited information is available for any species regarding acute toxicity. Minimum toxic doses have not been established; laboratory animals have tolerated massive doses up to 31.5 grams without lethal effect. If an overdose occurs, treatment should be **symptomatic and supportive**. Due to high protein binding, dialysis is unlikely to be effective.
VetSheet ์ฝ๋ฌผ ๋ ํผ๋ฐ์ค๋ ๋ฉดํ ์์ ์ ๋ฌธ๊ฐ๋ฅผ ์ํ ์์ ์์ฌ๊ฒฐ์ ๋ณด์กฐ ๋๊ตฌ์ด๋ฉฐ, ์ ๋ฌธ์ ํ๋จ์ด๋ ์ ์กฐ์ฌ์ ์ต์ ๋ผ๋ฒจ์ ๋์ ํ์ง ์์ต๋๋ค.